摘要:
Methods, compositions and kits for modulating demethylation in a mammalian cell are provided. Also provided are methods, compositions and kits for screening candidate agents for activity in modulating genomic DNA demethylation in mammalian cells. These methods, compositions and kits find use in producing induced pluripotent stem cells (iPS) and somatic cells in vitro and for treating human disorders including cancer and disorders arising from defects in genomic imprinting.
摘要:
본 발명은 배아줄기세포와 동일한 분화능을 가지는 맞춤형 만능줄기세포를 제조하는 방법에 관한 것으로, a)다양한 방법으로 유도된 모든 종류의 역분화 줄기세포 또는 유도만능줄기세포(induced Pluripotent Stem cells, iPS)에서 단백질을 분리하는 추출물 제조 단계; b)상기 추출물을 성체세포에 주입하는 단계; 및 c)추출물이 주입된 성체세포를 배양하여 배아줄기세포와 동일한 분화능을 가지는 만능줄기세포를 유도하는 단계를 포함한다. 또한, 본 발명은 상기 방법에 의해 제조된 만능줄기세포 및 상기 만능줄기세포를 포함하는 세포 치료제에 관한 것이다. 본 발명은 iPS 단백질 추출물을 사용하여 성체의 분화된 체세포로부터 만능줄기세포를 매우 용이하게 그리고 고효율로 제조하는 방법을 제공한다. 따라서 배아의 파괴라는 윤리적 문제를 발생시키지 아니하며, 현재까지 알려진 가장 일반적인 iPS 유도방법인 발암성 바이러스의 사용에 기인한 암발생의 위험이 없다. 이에 더하여 본 발명의 방법으로 유도된 만능줄기세포는 사용된 성체세포와 그 유전적 기원이 동일하므로 궁극적으로 면역거부반응이 없는 맞춤형 세포 치료제의 실용화에 크게 기여할 수 있을 것으로 기대된다.
摘要:
Particular aspects show that the signal peptide remains intact on the mature CD18 molecule on ruminant leukocytes rendering these cells susceptible to cytolysis by Lkt. Comparative amino acid sequence analysis of the signal peptide of CD18 of eight ruminants and five non-ruminants revealed that the ruminant CD18 signal peptides contain 'cleavage-inhibiting' glutamine (Q), compared to 'cleavage-conducive' glycine in non-ruminants, at position -5 relative to the cleavage site. Mutagenesis of Q at position -5 of the bovine CD18 signal peptide to G resulted in the abrogation of Lkt-mediated cytolysis of transfectants expressing bovine CD18 carrying the Q(-5)G mutation. Provided is novel technology to clone cattle and other ruminants expressing CD18 without the signal peptide on their leukocytes, providing ruminants that are less susceptible to M. haemolytica. Methods for treating conditions and/or diseases associated with M. haemolytica (e.g., pneumonic pasteurellosis), comprising administration of polypeptides comprising CD18 signal peptide sequences are also provided.
摘要:
The present invention relates to cellular differentiation and, in particular to hybrid cells that exhibit phenotypic plasticity and methods for producing these cells. The invention also relates to methods for generating specific cells of a desired phenotype. The invention still further relates to methods of producing hybrid cells with a capacity to de- differentiate into an earlier progenitor state. The invention further contemplates the use of hybrid cells in a range of applications, for example tissue generation.
摘要:
The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdmlß and C/EBPß activity and/or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of both Prdmlß and C/EBPß expression and/or activity. Further provided are methods for identifying compounds that are capable of modulating both Prdmlß and C/EBPß expression and/or activity.
摘要:
This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.
摘要:
Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Disclosure of a method to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Disclosure of a method to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment administering the patient-specific cell line to the patient.
摘要:
The invention provides a tumor cell genetically modified to express a nucleic acid encoding a secreted form of a heat shock protein (hsp) gp96 polypeptide. The invention also provides a method of stimulating an immune response to a tumor by administering a tumor cell genetically modified to express a nucleic acid encoding a secreted form of a gp96 polypeptide.
摘要:
The present invention discloses a method for reprogramming a differentiated cell to an undifferentiated stem cell comprising fusing a pluripotent cell with a differentiated cell to form a fused cell, wherein the pluripotent cell is pre-treated or the fused cell is treated with a suitable amount of a Wnt/β-catenin pathway activator.
摘要:
Изобретение относится к области клеточной инженерии и может быть использовано для получения гибридной стволовой клетки человека. Сущность способа состоит в том, что гибридную стволовую клетку получают путем межвидовой трансплантации ядра соматической клетки человека в энуклеированный ооцит, при этом в качестве донорской соматической клетки человека используют мезенхимную стволовую клетку, а в качестве ооцита используют ооцит свиньи. Также предложена гибридная стволовая клетка человека, полученная путем переноса ядра мезенхимальной стволовой клетки человека в энуклеированный ооцит свиньи. Техническим результатом является разработка способа, позволяющего получать гибридные стволовые клетки человека, генетический набор которых идентичен таковому пациента, при использовании которых в восстановительной терапии исключается вероятность возникновения иммунной несовместимости.